TABLE 1.
Pharmacokinetic parameters of telavancin in plasma and blister fluid
| Parametera | Mean ± SD inb:
|
|
|---|---|---|
| Plasma | Blister fluid | |
| Cmax (μg/ml) | 84.8 ± 5.3 | 16.0 ± 2.0 |
| Tmax (h) | 1.0 ± 0.0 | 9.3 ± 2.4 |
| AUCss (μg · h/ml) | 604 ± 83 | 241 ± 33 |
| Elimination t1/2 (h) | 6.26 ± 0.78 | 6.91 ± 0.53 |
| CL (ml/h/kg) | 11.8 ± 2.1 | |
| MRT (h) | 6.57 ± 0.42 | 10.3 ± 0.6 |
| Vss (ml/kg) | 98.0 ± 14.8 | |
a
t1/2, half-life; CL, clearance; MRT, mean residence time; Vss, volume of distribution at steady state.
b
Pharmacokinetics was determined after the administration of 7.5 mg/kg every 24 hours to healthy subjects (n = 8).